EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access

Olanzapine Plus Triple Antiemetic Therapy for the Prevention of Carboplatin-Induced Nausea and Vomiting: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial

Naoki Inui iD, Takahito Suzuki iD, Kazuki Tanaka iD, Masato Karayama iD, Yusuke Inoue iD, Kazutaka Mori iD, Hideki Yasui iD, Hironao Hozumi iD, Yuzo Suzuki iD, Kazuki Furuhashi, Tomoyuki Fujisawa iD, Shun Matsuura und 17 weitere

Journal of Clinical Oncology · 10.08.2024 · 42 (23) · 2780-2789

DOI: 10.1200/jco.24.00278 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.08.2024. Verfasst von Naoki Inui und 28 weiteren Autor:innen. Beteiligte Einrichtung: Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan. Hauptthemen laut MEDLINE: Olanzapine, Carboplatin, Nausea, Antiemetics. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE We evaluated the efficacy and safety of antiemetic therapy with olanzapine, a neurokinin-1 receptor antagonist (RA), a 5-hydroxytryptamine-3 (5-HT 3 ) RA, and dexamethasone for preventing chemotherapy-induced nausea and vomiting in patients receiving carboplatin-containing chemotherapy. PATIENTS AND METHODS Chemotherapy-naïve patients scheduled to receive carboplatin (AUC ≥5) were randomly assigned to receive either olanzapine 5 mg once daily (olanzapine group) or placebo (placebo group) in combination with aprepitant, a 5-HT 3 RA, and dexamethasone. The primary end point was the complete response (CR; no vomiting and no rescue therapy) rate in the overall phase (0-120 hours). Secondary end points included the proportion of patients free of nausea and safety. RESULTS In total, 355 patients (78.6% male, median age 72 years, 100% thoracic cancer), including 175 and 180 patients in the olanzapine and placebo groups, respectively, were evaluated. The overall CR rate was 86.9% in the olanzapine group versus 80.6% in the placebo group. The intergroup difference in the overall CR rate was 6.3% (95% CI, –1.3 to 13.9). The proportions of patients free of chemotherapy-induced nausea in the overall (88.6% in the olanzapine group v 75.0% in the placebo group) and delayed (89.7% v 75.6%, respectively) phases were significantly higher in the olanzapine group than in the placebo group (both P < .001). Somnolence was observed in 43 (24.6%) and 41 (22.9%) patients in the olanzapine and placebo groups, respectively, and no events were grade ≥3 in severity. CONCLUSION The addition of olanzapine was not associated with a significant increase in the overall CR rate. Regarding the prevention of nausea, adding olanzapine provided better control in patients receiving carboplatin-containing chemotherapy, which needs further exploration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OlanzapineCarboplatinNauseaAntiemeticsVomitingDexamethasoneAprepitantHumansMaleFemaleDouble-Blind MethodAgedMiddle AgedAged, 80 and overDrug Therapy, CombinationAdultBenzodiazepinesAntineoplastic AgentsMorpholinesNeoplasmsNeurokinin-1 Receptor Antagonists

Substanzen

OlanzapineCarboplatinAntiemeticsDexamethasoneAprepitantBenzodiazepinesAntineoplastic AgentsMorpholinesNeurokinin-1 Receptor Antagonists

Autor:innen und Institutionen

  • Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.
  • Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine, Hamamatsu, Japan.
  • Department of Respiratory Medicine, Fujieda Municipal General Hospital, Fujieda, Japan.
  • Department of Respiratory Medicine, Shizuoka City Shimizu Hospital, Shizuoka, Japan.
  • Department of Respiratory Medicine, Iwata City Hospital, Iwata, Japan.
  • Department of Respiratory Medicine, Seirei Mikatahara General Hospital, Hamamatsu, Japan.

ORCID-Profile: Naoki Inui, Takahito Suzuki, Kazuki Tanaka, Masato Karayama, Yusuke Inoue, Kazutaka Mori, Hideki Yasui, Hironao Hozumi, Yuzo Suzuki, Tomoyuki Fujisawa, Koji Nishimoto, Yutaro Tamiya, Yasuaki Mino, Noriyuki Enomoto

Zitieren

APA

Inui, N., Suzuki, T., Tanaka, K., Karayama, M., Inoue, Y., Mori, K., Yasui, H., Hozumi, H., Suzuki, Y., Furuhashi, K., Fujisawa, T., Matsuura, S., Nishimoto, K., Matsui, T., Asada, K., Hashimoto, D., Fujii, M., Niwa, M., Uehara, M., …, & Suda, T. (2024). Olanzapine Plus Triple Antiemetic Therapy for the Prevention of Carboplatin-Induced Nausea and Vomiting: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial. Journal of Clinical Oncology, 42(23), 2780-2789. https://doi.org/10.1200/jco.24.00278

Vancouver

Inui N, Suzuki T, Tanaka K, Karayama M, Inoue Y, Mori K, et al. Olanzapine Plus Triple Antiemetic Therapy for the Prevention of Carboplatin-Induced Nausea and Vomiting: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial. Journal of Clinical Oncology. 2024;42(23):2780-2789. doi:10.1200/jco.24.00278

BibTeX
@article{Inui2024,
  author = {Inui, Naoki and Suzuki, Takahito and Tanaka, Kazuki and Karayama, Masato and Inoue, Yusuke and Mori, Kazutaka and Yasui, Hideki and Hozumi, Hironao and Suzuki, Yuzo and Furuhashi, Kazuki and Fujisawa, Tomoyuki and Matsuura, Shun and Nishimoto, Koji and Matsui, Takashi and Asada, Kazuhiro and Hashimoto, Dai and Fujii, Masato and Niwa, Mitsuru and Uehara, Masahiro and Matsuda, Hiroyuki and Koda, Keigo and Ikeda, Masaki and Inami, Nao and Tamiya, Yutaro and Kato, Masato and Nakano, Hideki and Mino, Yasuaki and Enomoto, Noriyuki and Suda, Takafumi},
  title = {Olanzapine Plus Triple Antiemetic Therapy for the Prevention of Carboplatin-Induced Nausea and Vomiting: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  volume = {42},
  number = {23},
  pages = {2780--2789},
  doi = {10.1200/jco.24.00278}
}
Kostenlos starten →